Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,601.00-0.41%ETH$2,698.06-0.77%GOLD$4,194.40+0.17%OIL$89.74+0.34%
Smart Investors Daily
SID Premium
AI

NASDAQ · AIMD

Ainos, Inc.

Healthcare · Biotechnology

$1.33

Down-$0.04 (-3.01%)

Updated Oct 6, 2026, 10:16 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.91M
P/E ratio
-0.5
Dividend yield
0.00%
52-week range
$1.20 – $4.44
Volume
30.3K
Avg. volume
660.22K

Price performance · AIMD

AIMD price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

AIMD closed at $1.33 after 20 trading sessions, down 10.14% for the selected period.

Last close
$1.33
Period change
-10.14%
Period low
$1.24
Period high
$1.49
Daily close
View OHLC price history
AIMD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$1.349$1.37$1.3117$1.3330.3K
Oct 2, 2026$1.33$1.40$1.33$1.35351.19K
Oct 1, 2026$1.27$1.3599$1.2603$1.3041.9K
Sep 30, 2026$1.33$1.36$1.22$1.27136.98K
Sep 29, 2026$1.34$1.385$1.20$1.24227.02K
Sep 28, 2026$1.31$1.40$1.30$1.3382.31K
Sep 25, 2026$1.37$1.41$1.32$1.34162.49K
Sep 24, 2026$1.26$1.53$1.25$1.445.9M
Sep 23, 2026$1.37$1.45$1.37$1.39527.12K
Sep 22, 2026$1.48$1.48$1.37$1.4141.77K
Sep 21, 2026$1.47$1.48$1.40$1.4643.19K
Sep 18, 2026$1.46$1.49$1.3801$1.4851.66K
Sep 17, 2026$1.45$1.49$1.3658$1.4931.85K
Sep 16, 2026$1.37$1.4997$1.34$1.3867.66K
Sep 15, 2026$1.40$1.40$1.35$1.3726.48K
Sep 14, 2026$1.415$1.4299$1.37$1.3735.78K
Sep 11, 2026$1.48$1.48$1.40$1.4423.2K
Sep 10, 2026$1.45$1.46$1.4201$1.4314.65K
Sep 9, 2026$1.49$1.52$1.46$1.4834.23K
Sep 8, 2026$1.60$1.60$1.475$1.4841.54K

Latest AIMD news

The latest Smart Investors Daily articles mentioning AIMD.

Stock researchCompany · Overview

AIMD research

Overview

Company profile and research snapshot.

Company profile

Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment

Partner's Written Confirmation Fulfills Payment Conditions; Initial License Fee Payable Within 15 Business DaysHOUSTON, TX / ACCESS Newswire / September 30, 2026 / (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has completed the required data delivery and technology transfer under its VELDONA® license agreement, triggering a $600,000 initial license payment. The licensing partner confirmed completion in writing on September 29.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By